Conference Coverage

CGRP-targeted migraine prevention drugs succeed in phase II


 

FROM THE AAN 2014 ANNUAL MEETING

Drugs that hit CGRP may even help other headache types, Dr. Dodick added.

"There is some evidence that CGRP is also important in other serious headache disorders such as chronic migraine, medication overuse headache, and cluster headache – disorders that are currently very difficult to manage."

The ALD403 study was supported by Alder Biopharmaceuticals. The LY2951742 study was supported by Arteaus Therapeutics in conjunction with Eli Lily. Both Dr. Goadsby and Dr. Dodick have financial relationships with numerous pharmaceutical companies, including receiving research monies, and participating as officers or speakers.

msullivan@frontlinemedcom.com

Pages

Recommended Reading

Group issues recommendations for genetic susceptibility testing for carbamazepine skin reactions
MDedge Internal Medicine
Two definitions of Gulf War illness recommended
MDedge Internal Medicine
FDA okays first migraine prevention device
MDedge Internal Medicine
Sen. Manchin urges withdrawal of Zohydro approval
MDedge Internal Medicine
Routine neuroimaging for headache increasing despite guidelines
MDedge Internal Medicine
Topiramate approved for migraine prevention in adolescents
MDedge Internal Medicine
Naloxone autoinjector approved for caregiver use in treating opioid overdoses
MDedge Internal Medicine
Plasma fluoride levels tied to voriconazole-induced periostitis
MDedge Internal Medicine
VIDEO: Practice pearls for treating opiate dependence
MDedge Internal Medicine
Chinese herbal remedy found noninferior to methotrexate in RA patients
MDedge Internal Medicine